drugset / Trial / NCT01497275
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effects (good and bad) of the combination of ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory mantle cell lymphoma. Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with another monoclonal antibody called rituximab (Rituxan). It works by attaching to cancer cells and releasing radiation to damage those cells. Both Zevalin and Rituxan are given in this study, along with Velcade.
Timeline
- Start
- 2012-02
- Primary completion
- 2014-05
- Completion
- 2014-05
Outcome
Outcome not reported
Stopped (Enrollment): “Low accrual due to the approval of new drugs for use in Mantle cell lymphoma.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.5 mg/m2 | — |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.3 unknown | — |
| Subject | ibritumomab tiuxetan | Monoclonal antibody | 0.4 unknown | — |
| Background | Rituximab | Monoclonal antibody | 250 mg/m2 | — |